Jerome Alexandre
Overview
Explore the profile of Jerome Alexandre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
4137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Vigneron C, Charpentier J, Coussy F, Alexandre J, Pene F, Jamme M
Acta Oncol
. 2023 Apr;
62(4):358-363.
PMID: 37021781
Background: Breast cancer is the most prevalent neoplasm in women in North American and European countries. Data about intensive care unit (ICU) requirements and the related outcomes are scarce. Furthermore,...
12.
Ferron G, de Rauglaudre G, Becourt S, Delanoy N, Joly F, Lortholary A, et al.
Gynecol Oncol
. 2023 Jan;
170:186-194.
PMID: 36706645
Aim: The oral anti-angiogenic therapy nintedanib prolongs progression-free survival (PFS) when combined with chemotherapy after primary surgery for advanced epithelial ovarian cancer. The randomized phase II CHIVA trial evaluated the...
13.
Colomba E, Alexandre J, Le Teuff G, Genestie C, Coupez D, Coquard I, et al.
Gynecol Oncol
. 2022 Dec;
169:78-84.
PMID: 36521352
Background: Around 15% of metastatic endometrial carcinoma (EC) are MMRd/MSI-H improving response to immune checkpoint inhibitors (ICI). So far, few data existed considering the chemotherapy (CT) sensitivity in MMRd/MSI-H EC,...
14.
Vigneron C, Laousy O, Chassagnon G, Vakalopoulou M, Charpentier J, Alexandre J, et al.
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497352
Simple and accessible prognostic factors are paramount for solid cancer patients experiencing life-threatening complications. The aim of this study is to appraise the impact of functional and nutritional status and...
15.
Rodier T, Puszkiel A, Cardoso E, Balakirouchenane D, Narjoz C, Arrondeau J, et al.
Pharmaceutics
. 2022 Sep;
14(9).
PMID: 36145591
High interindividual variability (IIV) of the clinical response to epidermal growth factor receptor (EGFR) inhibitors such as osimertinib in non-small-cell lung cancer (NSCLC) might be related to the IIV in...
16.
Joly F, Fabbro M, Berton D, Lequesne J, Anota A, Puszkiel A, et al.
Gynecol Oncol
. 2022 Jul;
166(3):389-396.
PMID: 35902297
Background: Anti-angiogenic rechallenge with bevacizumab plus chemotherapy is effective in recurrent ovarian cancer (rOC); however, data are limited on tyrosine kinase inhibitors after progression on maintenance bevacizumab. Methods: In the...
17.
Courlet P, Cardoso E, Bandiera C, Stravodimou A, Zurcher J, Chtioui H, et al.
Pharmaceutics
. 2022 Jul;
14(7).
PMID: 35890213
Neutropenia is the most frequent dose-limiting toxicity reported in patients with metastatic breast cancer receiving palbociclib. The objective of this study was to investigate the pharmacokinetic-pharmacodynamic (PK/PD) relationships for toxicity...
18.
Longo-Munoz F, Castellano D, Alexandre J, Chawla S, Fernandez C, Kahatt C, et al.
Eur J Cancer
. 2022 Jul;
172:340-348.
PMID: 35830841
Background: Patients with neuroendocrine tumours (NETs) need alternative therapies after failure of first-line therapy. Patients And Methods: This phase II trial evaluated lurbinectedin, a selective inhibitor of oncogenic transcription, at...
19.
Noel J, Jouinot A, Alexandre J, Ulmann G, Bretagne M, Castel-Ajgal Z, et al.
Cancers (Basel)
. 2022 Jul;
14(13).
PMID: 35804986
Background: Nivolumab improved patients’ survival in metastatic renal cell carcinoma (mRCC). We aimed to evaluate resting energy expenditure (REE) (i.e., patients’ basal metabolism) to predict efficacy. Methods: We conducted a...
20.
Beinse G, Just P, LE Frere Belda M, Laurent-Puig P, Jacques S, Koual M, et al.
Br J Cancer
. 2022 Jun;
127(6):1123-1132.
PMID: 35752712
Background: Molecular alterations leading to homologous recombination deficiency (HRD) are heterogeneous. We aimed to identify a transcriptional profile shared by endometrial (UCEC), breast (BRCA) and ovarian (OV) cancers with HRD....